ENCell Presents EN001 Clinical Results at U.S. Charcot-Marie-Tooth Disease 1E International Conference

ENCell, a company specializing in advanced biopharmaceutical CDMO (Contract Development and Manufacturing Organization) and new drug development, announced on October 17 that it hosted the "MSC for CMT Community" session at the international conference on Charcot-Marie-Tooth disease (CMT) 1E held in Boston, USA last month.

Through this session, ENCell broadly introduced the therapeutic potential and limitations of mesenchymal stem cells (MSC) to the medical and patient communities, considering that MSCs are still a relatively unfamiliar treatment platform in the CMT field. The session featured presentations by Professor Susan Prockop of Harvard Medical School, Professor Fernando A. Fierro of the University of California, Davis (UC-Davis), and ENCell’s own specialist, Choi Younghwan, MD, Ph.D.

CMT is a representative peripheral nerve disorder that causes deformities of the hands and feet and muscle atrophy. As time passes, patients experience increasing difficulty walking and a gradual decline in their ability to live independently. It is a progressive rare disease that significantly reduces quality of life due to symptoms such as pain, sensory loss, and balance disorders. However, no approved treatments are currently available.

Professor Susan Prockop shared her clinical experience with "Ryoncil," the MSC therapy developed by Mesoblast and the world’s first to receive FDA approval. She stated, "Mesenchymal stem cells have consistently demonstrated safety through accumulated clinical experience. Recent regulatory milestones, such as the FDA approval of Ryoncil, are important cases that reaffirm the safety and therapeutic potential of MSCs."

Professor Fernando A. Fierro then discussed the long-term safety and therapeutic potential of MSCs, saying, "It is encouraging to introduce the safety and therapeutic possibilities of mesenchymal stem cells, which I have researched for over 20 years, to the CMT community. I sincerely hope that ENCell’s EN001 will be rapidly developed and bring meaningful changes to patients’ lives."

Additionally, Alexandre Hoyau, president of CMT-France and a CMT1E patient who attended the conference, expressed that he was deeply impressed by the clinical results of EN001. He remarked, "It was a meaningful opportunity to confirm the safety and efficacy of EN001 for CMT 1E patients. I sincerely hope that, through Korea’s Advanced Regenerative Medicine Act, EN001 will soon become a treatment opportunity for CMT1E patients."

Choi Younghwan, MD at ENCell, stated, "EN001 is currently undergoing an integrated phase 1b/2a clinical trial in Korea at a rapid and efficient pace, and it received significant attention at this conference. As requests for clinical participation from overseas patient associations continue to increase, we will do our utmost to quickly provide treatment opportunities to CMT patients and pursue global technology licensing."

Meanwhile, ENCell successfully completed a clinical study for CMT 1E patients last year and is currently preparing to launch advanced regenerative therapy in collaboration with Samsung Medical Center.

This content was produced with the assistance of AI translation services.